BioNTech & OncoC4 announced a collaboration for a CTLA-4 mAb

CAR-T Digest - August 2020

Weekly Digest - 18-24 Mar 2023

March 20, 2023: ONC-392 (IV)/ Solid tumors/ BioNTech & OncoC4: Announced a collaboration to co-develop & commercialize a novel checkpoint antibody

BioNTech and OncoC4 collaborated to co-develop and market ONC-392, from OncoC4, as a monotherapy or in combination with anti-PD1 for a variety of cancer indications
- Transaction to close in H1’23
OncoC4 will receive $200 M and is eligible to receive development, regulatory, and commercial milestone payments as well as double-digit tiered royalties
ONC-392, a next-gen anti-CTLA-4 antibody inhibiting immune cell activity by deleting immunosuppressive T-cells in the tumor environment
- Phase 1/2 trial NCT04140526 is recruiting participants with advanced or metastatic solid tumors and NSCLC
- ONC-392 is dosed as mono 0.1mg/kg – 10mg/kg Q3W IV and in combination with Pembrolizumab (200mg Q3W)
“Despite being a prime target for more than a decade, we believe that targeting CTLA-4 has not reached its full potential in cancer immunotherapy,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech